Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 14,922 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disorders Clear all
Terminated Phase 2 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

NCT00953706
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2015 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911
View directory record Official record
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

NCT00372944
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
AZD6244, capecitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Alhambra, California • Bakersfield, California • Palm Springs, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 19, 2026, 10:25 PM EDT
Active, not recruiting No phase listed Observational

Colorectal Cancer Screening in Cystic Fibrosis

NCT05362344
View directory record Official record
Conditions
Cystic Fibrosis, Colorectal Cancer, Adenoma
Interventions
Stool tests
Procedure
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

NCT04672434
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor
Interventions
Sym021, Sym024
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 19, 2026, 10:25 PM EDT
Suspended Not applicable Interventional

RCT of Mobile Apps & FitBit v. Usual Care

NCT03623464
View directory record Official record
Conditions
Pancreatic Cancer, Gastric Cancer, Hepatic Cancer, Colon Cancer, Rectal Cancer, Small Bowel Cancer
Interventions
Mobile health application and Fitbit + standard of care, Standard of care
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease

NCT00250198
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 10:25 PM EDT
Terminated Phase 2 Interventional Results available

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
View directory record Official record
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 10:25 PM EDT
Recruiting Not applicable Interventional

vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC

NCT05727787
View directory record Official record
Conditions
Liver Cancer
Interventions
Stereotactic Body Radiation Treatment
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 19, 2026, 10:25 PM EDT
Terminated Not applicable Interventional Results available

Conventional Direct Laryngoscopy Vs. Video Laryngoscopy With The C-MAC For Pyloromyotomy

NCT02775214
View directory record Official record
Conditions
Pyloric Stenosis, Intubation, Pediatric
Interventions
Video Laryngoscopy
Device
Lead sponsor
Indiana University
Other
Eligibility
Up to 6 Months
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 19, 2026, 10:25 PM EDT
Terminated Not applicable Interventional

Treatment of Chronic Cryptosporidiosis in AIDS Patients

NCT00001128
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Interleukin-12, Paromomycin sulfate, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 19, 2026, 10:25 PM EDT
Terminated Phase 2 Interventional Results available

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

NCT00127036
View directory record Official record
Conditions
Adenocarcinoma, Colon Cancer
Interventions
XELOX, XELIRI, Bevacizumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
12
States / cities
Deerfield Beach, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 19, 2026, 10:25 PM EDT
Terminated No phase listed Observational

Permission to Collect Blood Over Time for Research

NCT00767234
View directory record Official record
Conditions
Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatobiliary Neoplasm, Liver Carcinoma, Gallbladder Carcinoma, Bile Duct Carcinoma, Carcinoma of the Large Intestine, Anal Cancer
Interventions
Observation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

NCT00303264
View directory record Official record
Conditions
Dyspepsia
Interventions
dexloxiglumide, Nexium (esomeprazole)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 3 Interventional

Early Versus Interval Appendectomy for Ruptured Appendicitis in Children

NCT00435032
View directory record Official record
Conditions
Ruptured Appendicitis
Interventions
early appendectomy, interval appendectomy
Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
Up to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

NCT00813163
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
PEP02
Drug
Lead sponsor
PharmaEngine
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 19, 2026, 10:25 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06218914
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
Interventions
NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2043
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 10:25 PM EDT
Active, not recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics

NCT05986916
View directory record Official record
Conditions
NAFLD, Nonalcoholic Fatty Liver
Interventions
Liverscope® exam, MR exam, FibroScan® exam (optional), Blood draw, Body measurements, Questionnaires
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Emergency Ultrasound of the Gallbladder

NCT00388830
View directory record Official record
Conditions
Gallbladder Diseases
Interventions
Ultrasound
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 19, 2026, 10:25 PM EDT
Not yet recruiting Phase 2 Interventional

Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

NCT07765836
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
vilastobart (XTX101), Retifanlimab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

NCT03245736
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
Interventions
Tisotumab Vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery

NCT00003798
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
motexafin gadolinium, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 19, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 10:25 PM EDT
Completed No phase listed Observational

Molecular Phenotypes for Cystic Fibrosis Lung Disease

NCT01116414
View directory record Official record
Conditions
Cystic Fibrosis, Lung Diseases
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 19, 2026, 10:25 PM EDT